C12N 2750/14032
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2750/14032 (Use of virus as therapeutic agent, other than vaccine) appears on 14 US grants and 25 published applications in this corpus.
Search patents in C12N- Granted patents
- 14
- Published applications
- 25
- Assignees
- 23
- Inventors
- 40
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 2 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 2 | 1 |
| 2013 | 2 | 0 |
| 2014 | 0 | 2 |
| 2015 | 1 | 1 |
| 2016 | 0 | 1 |
| 2017 | 0 | 2 |
| 2018 | 1 | 2 |
| 2019 | 2 | 1 |
| 2020 | 2 | 3 |
| 2021 | 0 | 2 |
| 2022 | 1 | 1 |
| 2023 | 1 | 1 |
| 2024 | 0 | 0 |
| 2025 | 0 | 3 |
| 2026 | 2 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency29 Sep 2026US 12,747,429 B2The Trustees of the University of Pennsylvania
- Method for predicting the clinical response of oncolytic parvovirus H1 (H-1PV) treatment in a patient suspected of suffering from cancer by measuring the expression levels of laminins and/or galectins as biomarkers in a patient's sample6 Jan 2026US 12,516,381 B2Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency22 Aug 2023US 11,732,246 B2The Trustees of the University of Pennsylvania
- Murine parvovirus and uses thereof17 May 2022US 11,332,720 B2Centenary Institute of Cancer Medicine and Cell Biology
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency22 Sep 2020US 10,781,430 B2The Trustees of the University of Pennsylvania
- Adeno-associated virus vector encoding connexin 26 and uses thereof17 Sep 2026US 2026/0275381 A1
- Modified oncolytic parvovirus h-1pv with an enhanced fitness and superior anticancer activity21 Aug 2025US 2025/0262296 A1
- Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy due to energy failure3 Apr 2025US 2025/0109407 A1Assistance Publique-HôPitaux De Paris (Aphp)
- Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure3 Apr 2025US 2025/0109408 A1
- Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency28 Dec 2023US 2023/0416700 A1The Trustees of the University of Pennsylvania
Most cited
By later US patents
- Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia26US 9,066,966 B2Assistance Publique-HôPitaux De Paris (Aphp) · 2015
- Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy due to Friedreich ataxia13US 10,337,027 B2Aphp (Assistance Publique - HôPitaux De Paris) · 2019
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency13US 9,890,365 B2The Trustees of the University of Pennsylvania · 2018
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency10US 10,167,454 B2The Trustees of the University of Pennsylvania · 2019
- Parvovirus cancer therapy and combination with chemotherapy7US 8,414,883 B2Deutsches Krebsforschungszentrum · 2013